- Lobbying
- Lobbying by Vifor International AG (CSL Vifor)
Lobbying Relationship
Bills mentioned
H.R.5074: Kidney PATIENT Act of 2023
Sponsor: Buddy Carter (R-Ga.)
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist | Covered positions? |
---|---|
Cheryl Jaeger | Shared employee, Ofc of the Speaker & Ofc of VA 07; Sr Policy Adv, Maj Leader, Rep. Cantor; Sr Policy Adv, Republican Whip, Rep. Cantor; Sr Policy Adv, Majority Whip, Rep. Blunt; Prof Staff House Committee on E & C; Sr LA to Rep. Cox |
Jason Van Pelt | Legislative Director, Senior Legislative Asst, Legislative Asst, Staff Asst: Rep. Ed Whitfield |
Brittany Hernandez | Senior Legislative Assistant, Legislative Assistant, Legislative Correspondent, Staff Assistant: Rep. Steve Cohen |
Ivelisse Porroa-Garcia | Policy Director, Congressional Hispanic Caucus (CHC); Legislative Assistant, Rep. Raul Ruiz; Staff Assistant, Sen. Barbara Boxer |
Jason Gleason | Chief of Staff/Legislative Director, Rep. John Sarbanes; Legislative Director/Legislative Asst/Legislative Correspondent/Staff Asst, Sen. Paul Sarbanes |
Mathew Lapinski | n/a |
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
Q1 Report
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Registration
Issue(s) they said they’d lobby about: General education about end stage renal disease (ESRD) and kidney disease policies, including Medicare beneficiary access to pharmaceuticals..
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate